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ABSTRACT
Introduction Idiopathic pulmonary fibrosis (IPF) is a 
progressive fibrosing interstitial lung disease of unknown 
aetiology and cure. Recent studies have reported a 
dysregulation of exosomal microRNAs (miRs) in the IPF 
context. However, the impact of IPF- related exosomal 
miRs on the progression of pulmonary fibrosis is 
unknown.
Methods Two independent cohorts were enrolled 
at the ambulatory care polyclinic of Liège University. 
Exosomes from sputum were obtained from 19 patients 
with IPF and 23 healthy subjects (HSs) (cohort 1), and 
the ones from plasma derived from 14 patients with IPF 
and 14 HSs (cohort 2). Exosomal miR expression was 
performed by quantitative reverse transcription–PCR. The 
functional role of exosomal miRs was assessed in vitro by 
transfecting miR mimics in human alveolar epithelial cells 
and lung fibroblasts.
Results Exosomal miR analysis showed that miR-142- 
3p was significantly upregulated in sputum and plasma 
of patients with IPF (8.06- fold, p<0.0001; 1.64 fold, 
p=0.008, respectively). Correlation analysis revealed a 
positive association between exosomal miR-142- 3p and 
the percentage of macrophages from sputum of patients 
with IPF (r=0.576, p=0.012), suggesting macrophage 
origin of exosomal miR-142- 3p upregulation. The 
overexpression of miR-142- 3p in alveolar epithelial cells 
and lung fibroblasts was able to reduce the expression of 
transforming growth factor β receptor 1 (TGFβ-R1) and 
profibrotic genes. Furthermore, exosomes isolated from 
macrophages present antifibrotic properties due in part 
to the repression of TGFβ-R1 by miR-142- 3p transfer in 
target cells.
Discussion Our results suggest that macrophage- 
derived exosomes may fight against pulmonary fibrosis 
progression via the delivery of antifibrotic miR-142–3 p 
to alveolar epithelial cells and lung fibroblasts.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progres-
sive fibrosing interstitial lung disease of unknown 
aetiology and cure, which leads to rapid death, 
within 2–3 years after diagnosis.1–4 IPF is charac-
terised by progressive and irreversible destruction 
of the lung architecture caused by fibrotic ‘scar’ 
formation that ultimately leads to organ destruc-
tion and death from respiratory failure.5 6 Its physi-
opathology remains poorly characterised, although 
recent studies suggest that this disease results from 
aberrant dysregulated wound healing response 
following chronic alveolar epithelial injury and 
aberrant proliferation of fibroblasts.7 Genetic 
predispositions and environmental factors (such as 
smoking, gastro- oesophageal reflux), as well as cell 
senescence associated with ageing appear to be key 
factors in IPF pathophysiology.8–10 Its clinical prog-
nosis has recently improved since the discovery of 
new efficient therapeutic agents, pirfenidone and 
nintedanib.2 11 Yet, these therapies only slow disease 
progression and do not provide a definitive cure. 
Novel therapeutics are desperately needed.
MicroRNAs (miRs) are small non- coding 
RNA molecules (20–22 nucleotides) that post- 
transcriptionally modulate gene expression by 
regulating the stability and/or translation of target 
messenger RNAs (mRNAs) by binding to the 3′ 
untranslated region of mRNAs.12 13 MiRs have 
emerged as potent modulators of various cellular 
processes such as proliferation, migration, differen-
tiation, inflammation and their utility as biomarkers 
of pulmonary fibrosis is being explored.14–18 Indeed, 
Lui et al found an upregulation of miR-21- 5p in 
Key messages
What is the key question?
 ► What is the impact of idiopathic pulmonary 
fibrosis (IPF)- related exosomal microRNA 
(miR)-142- 3p on the progression of pulmonary 
fibrosis?
What is the bottom line?
 ► Correlation analysis revealed that the 
expression of sputum exosomal miR-142- 3p is 
positively associated with sputum macrophages 
of patients with IPF, suggesting its macrophage 
origin.
 ► Macrophage- derived exosomes present 
antifibrotic properties due in part to the transfer 
of miR-142- 3p to alveolar epithelial cells and 
lung fibroblasts.
Why read on?
 ► This study provides novel insights into the 
potential protective role of macrophage- derived 
exosomes in IPF context.
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the lungs of patients with IPF and its profibrotic properties 
by promoting the activity of transforming growth factor β1 
(TGF-β1) in pulmonary fibroblasts.19 On the other hand, other 
studies reported that the levels of miR- 200c- 5p,20 miR- 26a- 5p,21 
miR-29- 5p22 and Let- 7d- 5p23 were reduced in the lungs of mice 
with experimental pulmonary fibrosis and/or in the lungs of 
patients with IPF, and their overexpression attenuates experi-
mental pulmonary fibrosis in mice. However, the role of miRs in 
the pathogenesis of lung fibrosis has just begun to be elucidated. 
Further studies on the role of these molecules on lung fibrosis 
could help us to develop new therapeutic strategies for IPF.
Exosomes are small vesicles (30–150 nm) that are constitutively 
secreted into biofluids (eg, blood24 and bronchoalveolar lavage 
fluid25) by several cell types, including alveolar epithelial cells, 
fibroblasts and inflammatory cells, and contain numerous bioac-
tive molecules, such as nucleic acids (including miRs), proteins 
and lipids.26 Their content varies according to the state of their 
parental cells and is thus reflective of the cellular context.27 
Several studies reported that exosomes regulate various signal-
ling pathways, including inflammatory and angiogenic path-
ways, by transferring miRs from a donor to a recipient cell.28–30 
Exosomes and miRs appear to contribute to pulmonary fibrosis, 
as the size, quantity, content and function of exosomes vary with 
inflammation and epithelial damage,27 31 and several miRs are 
known to modulate fibrosis pathways.19–22 A limited number of 
studies have reported the role of exosomes on the pathogenesis 
of pulmonary fibrosis.17 31 32 However, to our knowledge, no 
study has reported the impact of exosomal miRs derived from 
sputum on the pathogenesis of pulmonary fibrosis.
Previously, we have identified three miRs showing an aberrant 
expression in sputum- derived exosomes from patients with IPF 
compared with healthy subjects (HSs) (miR-142- 3p, miR- 33a- 5p 
and let- 7d- 5p).33 In the current study, we sought to determine 
the impact of these miRs on fibrosis associated to IPF progres-
sion. Our results suggest that (1) sputum macrophages are the 
source of elevated levels of exosomal miR-142- 3p in IPF context; 
and (2) macrophage- derived exosomes exert a protective effect 
against pulmonary fibrosis progression via the delivery of antifi-
brotic miR-142- 3p.
METHODS
Demographic and clinical characteristics of cohorts
Two independent study populations were enrolled at the ambu-
latory care polyclinics of Liège University. The diagnosis of 
(definite) IPF was made according to the international recom-
mendations of the American Thoracic Society/European Respi-
ratory Society34 (more information in online supplementary 
methods). The first cohort of 19 patients with IPF and 23 HSs 
was used to study the alteration of exosomal miR levels in the 
sputum, whereas the second cohort of 14 patients with IPF and 
14 HSs was used to study the alteration of exosomal miR levels 
in the plasma. Tables 1 and 2 provide an overview of the demo-
graphic and clinical characteristics of the 42 subjects from the 
first cohort (sputum cohort) and 28 subjects from the second 
cohort (plasma cohort). In both cohorts, patients with IPF 
exhibit a restrictive respiratory pattern.
Sputum induction and processing
After premedication with 400 μg inhaled salbutamol, sputum 
was induced by inhalation of hypertonic (NaCl 5%) or isotonic 
(NaCl 0.9%) saline according to the forcedexpiratory volume in 
one second value (greater than or less than 65% predicted). The 
whole sputum was collected in a plastic container, weighed and 
homogenised by adding three volumes of phosphate- buffered 
saline, vortexed for 30 s and centrifuged at 800 g for 10 min at 
4°C. The supernatant was separated from the cell pellet and 
stored at −80°C.35
Plasma processing
Blood was collected and transferred to EDTA- containing tubes. 
Plasma was isolated from the blood by centrifugation at 1500 g 
for 10 min at 4°C to remove blood cells, then the supernatant 
was centrifuged at 3000 g for 15 min at 4°C to remove platelets 
and cell debris. Plasma was stored at −80°C.
Isolation of exosomes from biofluids (sputum and plasma) 
or culture medium, dynamic light scattering, western blotting, 
quantitative reverse transcription–PCR (qRT- PCR), cell culture/
treatments/transfection/5- Bromo-2'-Deoxyuridine (BrdU) assay 
and in silico analysis.
Detailed methodology can be found in the online supplemen-
tary methods.
Statistical analysis
Statistical analysis was performed using SPSS Statistics for 
Windows software V.20 or GraphPad Prism V.8. A p value of 
less than 0.05 was considered to be statistically significant. For 
the analysis of subject characteristics, the values are expressed 
as mean±SD or median (IQR). Comparisons between groups 
were performed either with parametric unpaired two- tailed 
Student’s t- test or non- parametric two- tailed Mann- Whitney 
test. Differences in categorical data were compared using χ2 test. 
Table 1 Demographic and clinical characteristics of patients with HS 
and IPF enrolled in the sputum- exosomal microRNA study (cohort 1)
Cohort 1 HS (n=23) IPF (n=19) P value
Demographic characteristics
  Age (years) 64±4 68±14 0.2298
  Gender (M/F) 8/15 13/6 0.0616
  BMI (kg/m²) 26±4,33 27±4,89 0.6148
  Smokers (NS/FS/S) 8/9/6 4/12/13 0.1574
Functional characteristics and therapy
  FEV1 post-BD, %pred. 105±18 75±16 0.0000
  FVC post- BD, %pred. 114±21 74±19 0.0000
  FEV1/FVC post- BD, %pred. 76±5,42 81±9,87 0.0660
  TLC, %pred. – 69±19
  DLCO, %pred. – 47±41
  KCO, %pred. – 61±17
  Immunosuppressor: yes (%) – 27
  OCS: yes (%) – 54
Sputum characteristics
  Neutrophil % 78 (61–84) 73 (66–88) 0.9025
  Macrophage % 17 (13–33) 16 (8–26) 0.1312
  Lymphocyte % 1.6 (0.5–2.25) 1.2 (0.3–4) 0.8486
  Eosinophil % 0.3 (0–1) 0.1 (0–3.2) 0.7537
Data are presented as mean±SD or median (IQR).
*P value in bold indicate statistically significant differences between groups
BD, bronchodilator test; BMI, body mass index; DLCO, diffusing capacity of the 
lung for carbon monoxide; F, female; FEV1, forced expiratory volume in one second; 
FS, former smoker; FVC, forced vital capacity; HS, healthy subject; IPF, idiopathic 
pulmonary fibrosis; KCO, transfer coefficient; M, male; NS, non- smoker; OCS, oral 
corticosteroid; %pred., per cent predicted; S, smoker; TLC, total lung capacity.
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For comparison of miR expression in exosomes from patients 
with IPF versus HSs, data were not- normally distributed and are 
analysed using non- parametric two- tailed Mann- Whitney test, 
followed by Bonferroni- Dunn correction. P values were adjusted 
for age and sex using the general linear model; age and sex were 
entered into the analysis as covariates. For correlation analysis 
between miR levels and sputum cell counts (%), data were not 
normally distributed and analysed unsing Spearman’s correla-
tion. Individual data points are shown in all plots and repre-
sent data from independent cell culture experiments. For cell 
culture experiments, normality distribution was assessed with 
Shapiro- Wilk normality test. Variables with normal distribution 
are summarised as mean (±SEM) and with statistical compar-
ison between two groups performed using paired two- tailed 
Student’s t- test.
RESULTS
Exosomal miR-142-3p levels are increased in induced sputum 
and plasma of patients with IPF
Previously, we identified a unique signature of three miRs 
(miR-142- 3p, miR- 33a- 5p and Let- 7d- 5p) as potential 
biomarkers for IPF from sputum- derived exosomes.33 Here, we 
sought to determine whether these miRs are also dysregulated in 
the plasma of patients with IPF. For this, we first increased the 
sample size of the sputum cohort by isolating exosomes from the 
sputum of nine HSs and three patients with IPF using standard 
ultracentrifugation protocol (as described in Njock et al33) for a 
total of 23 HSs and 19 patients with IPF. In parallel, we isolated 
exosomes from the plasma of 14 HSs and 14 patients with IPF. 
The demographic and clinical characteristics of the subjects were 
listed in table 1 (sputum cohort) and table 2 (plasma cohort). The 
isolated vesicles from sputum and plasma had an average size 
distribution of 140 nm (±19.1) (figure 1A) and 51.8 nm (±10.2) 
(figure 1C), respectively, typical size distribution of exosomes. 
Furthermore, these isolated vesicles present an enrichment 
of several exosomal markers, CD63, CD81 and CD9, and an 
absence of mitochondrial cytochrome c (figure 1B,D), which 
confirm the purity of our sputum- derived and plasma- derived 
exosome preparations.
Then, we compared the expression levels of six IPF- related 
miRs in induced sputum and plasma between patients with IPF 
and HSs. For this, we chose to study six IPF- related miRs iden-
tified previously in sputum (miR-142- 3p, miR- 33a- 5p and Let- 
7d- 5p)33 and plasma/serum (miR-21- 5p,14 16 miR- 200c- 5p20 or 
miR- 26a- 5p21) of patients with IPF. We confirmed an alteration 
of miR- 33a- 5p (2.73 fold, p=0.0008) and Let- 7d- 5p (−1.78 
fold, p=0.0009) in IPF- sputum exosomes, and miR- 200c- 5p 
(2.21 fold, p=0.012) in IPF- plasma exosomes compared with 
corresponding HS- exosomes (figure 1E). Interestingly, only 
miR-142- 3p was dysregulated similarly in sputum- derived and 
plasma- derived exosomes from patients with IPF compared 
with HS (figure 1E). The elevation of exosomal miR-142- 3p is 
more pronounced in the sputum (8.06- fold, p<0.0001) than the 
plasma (1.64 fold, p=0.008) of IPF patients (figure 1E). The 
results were also significant after adjusting for age and gender 
distribution (table 3).
Our results show that among the six miRs that we investi-
gated, only miR-142- 3p is altered in exosomes from sputum and 
plasma of IPF patients (figure 1F), suggesting its major role in 
IPF pathophysiology.
Cellular origin responsible for the elevation of exosomal miR-
142-3p in IPF sputum
In a previous study, we have sorted sputum cell subsets using 
flow cytometry and detected the expression of miR-142- 3p in 
sputum macrophages and neutrophils.36 To investigate the cell 
subsets responsible for the elevation of exosomal miR-142- 3p 
in IPF sputum, we performed correlation analysis between miR 
expression levels and sputum cell subsets, particularly sputum 
macrophages and neutrophils (figure 2). This analysis revealed 
that the level of exosomal miR-142- 3p was positively associ-
ated with the percentage of sputum macrophages (Spearman 
r=0.576, p=0.012) (figure 2A) and was negatively associ-
ated with the percentage of sputum neutrophils (Spearman 
r=−0.611, p=0.007) of patients with IPF (figure 2D), suggesting 
that macrophages are responsible for the elevation of exosomal 
miR-142- 3p in IPF sputum. In addition, there was a positive 
correlation between exosomal Let- 7d- 5p and the percentage of 
sputum neutrophils (Spearman r=0.522, p=0.033) (figure 2F). 
There is no correlation between miR expression levels and 
lymphocytes or eosinophils from IPF sputum (online supplemen-
tary figure S1). In a physiological context, we did not observe 
any correlation between exosomal miR expression levels and 
sputum macrophages or neutrophils (online supplementary 
figure S2). Taken together, these results suggest that macro-
phages are responsible for the high level of sputum exosomal 
miR-142- 3p in the IPF context.
Biological pathways associated with IPF-related MiRs
In order to elucidate the potential role of IPF- related miRs 
(miR-142- 3p, miR- 33a- 5p and Let- 7d- 5p), we subjected them to 
in silico analysis with mirPath V.3 using Tarbase V.7 database. The 
analysis revealed that these miRs were involved in the regulation 
of transforming growth factor β (TGF-β) signalling pathway 
(false discovery rate (FDR)=1.45E-6) (figure 3A), a major process 
involved in the initiation and progression of pulmonary fibrosis 
by inducing epithelial cell/fibroblast differentiation, migration, 
Table 2 Demographic and clinical characteristics of patients with HS 







  Age (years) 62±3 71±9 0.1057
  Gender (M/F) 5/9 12/2 0.0183
  BMI (kg/m²) 26±5,34 28±5 0.2703
  Smokers (NS/FS/S) 4/8/2 1/13/0 0.0825
Functional characteristics and therapy
  FEV1 post- BD, %pred. 107±21 76±14 0.0000
  FVC post- BD, %pred. 113±24 77±16 0.0000
  FEV1/FVC post- BD, %pred. 77±3,78 76±11 0.7384
  TLC, %pred. – 75±21
  DLCO, %pred. – 41±16
  KCO, %pred. – 64±22
  Immunosuppressor: yes (%) – 33
  OCS: yes (%) – 38
Data are presented as mean±SD or median (IQR).
*P value in bold indicate statistically significant differences between groups
BD, bronchodilator test; BMI, body mass index; DLCO, diffusing capacity of the 
lung for carbon monoxide; F, female; FEV1, forced expiratory volume in one second; 
FS, former smoker; FVC, forced vital capacity; HS, healthy subject; IPF, idiopathic 
pulmonary fibrosis; KCO, transfer coefficient; M, male; NS, non- smoker; OC, oral 
corticosteroid; %pred., per cent predicted; S, smoker; TLC, total lung capacity.
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Figure 1 miR-142- 3p is upregulated in sputum- derived and plasma- derived exosomes of patients with IPF compared with HS. (A,C) Representative 
size distribution of purified exosomes from (A) sputum and (C) plasma by dynamic light scattering analysis. A representative experiment of 3 is shown. 
(B,D) Western blot analysis of exosomal markers, CD63, CD81, CD9, and mitochondrial protein cytochrome c in lysates from (B) sputum- derived and 
(D) plasma- derived exosomes and cell lysate (A549 cells). (E) Quantitative real- time PCR analysis of specific miRs in sputum- derived and plasma- 
derived exosomes of patients with IPF (n=19 for IPF sputum, n=14 for IPF plasma) compared with HS (n=23 for HS sputum, n=14 for HS plasma). 
Data are non- normally distributed and are analysed using a non- parametric two- tailed Mann- Whitney test, followed by Bonferroni- Dunn correction. 
(F) Venn diagram of the dysregulated miRs in sputum and plasma of patients with IPF. miRs in blue and red circles represent the sputum- deregulated 
and plasma- deregulated miRs, respectively. HS, healthy subject; miR, microRNA; IPF, idiopathic pulmonary fibrosis.
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invasion and deposition of extracellular matrix (ECM).5 Among 
the direct targets belonging to the TGF-β signalling pathway, the 
receptor transforming growth factor β receptor 1 (TGFβ-R1) 
was identified as a common target for the three IPF- related miRs 
(online supplementary figure S3).
miR-142-3P represses TGF-β-induced fibrotic response in 
alveolar epithelial cells and lung fibroblasts by targeting 
TGFβ-R1
We next sought to investigate the biological effect of IPF- related 
miRs on fibrotic response. For this, miR-142- 3p and miR- 33a- 5p 
were overexpressed by mimic transfection in A549 alveolar 
epithelial cells, and MRC5 lung fibroblasts and their impact on 
the expression of TGFβ-R1 were assessed. The overexpression 
of miR-142- 3p reduces the expression of TGFβ-R1 mRNA in 
A549 and MRC5 cells (figure 3B,C). To validate our findings, we 
also confirmed the regulation in primary lung fibroblasts (human 
lung fibroblast (HLF)) (figure 3D). Then, we confirmed the 
reduction of TGFβ-R1 at protein level in A549 and MRC5 cells 
by miR-142- 3p mimic (figure 3E–H). The overexpression of 
miR- 33a- 5p in A549 and MRC5 cells did not affect the expres-
sion of the TGFβ-R1 transcript (online supplementary figure S4).
As miR-142- 3p reduced the expression of TGFβ-R1, a key 
element of TGF-β signalling, we anticipated that this miR would 
display antifibrotic properties. Indeed, our results showed that 
miR-142- 3p suppressed the induction of the profibrotic genes 
by TGF-β stimulation in A549 alveolar epithelial cells (COL1A1, 
p=0.001; COL3A1, p=0.001; and TGF-β1, p=0.006) (figure 3I) 
and in MRC5 lung fibroblasts (COL1A1, p=0.006, and TGF-β1, 
p=0.017) (figure 3J). The antifibrotic effect of miR-142–3 p was 
also observed in primary lung fibroblasts (HLF) (suppression of 
the expression of COL1A1, p=0.041, and TGF-β1, p=0.007) 
(figure 3K).
We also investigated the impact of miR-142- 3p on the prolifer-
ation of A549 and MRC5, as aberrant proliferation of fibroblasts 
plays a critical role in the pathogenesis of pulmonary fibrosis. 
Interestingly, mir-142- 3p was able to reduce the proliferation of 
A549 (p=0.018) and MRC5 (p=0.048) cells (online supplemen-
tary figure S5).
These data highlight the antifibrotic property of miR-142- 3p 
in lung epithelial cells and fibroblasts via the targeting of TGFβ-
R1. In addition, miR-142- 3p is able to repress lung fibroblast 
proliferation.
Macrophage-derived exosomes transfer miR-142-3p to 
recipient lung epithelial cells and fibroblasts
Because our results suggest that sputum macrophages are respon-
sible of the elevated level of exosomal miR-142- 3p in the IPF 
context, the next step was to study the impact of macrophage- 
derived exosomes on the expression of profibrotic genes. To 
this end, we isolated exosomes from culture medium of THP1 
Table 3 General linear model to adjust p values for age and gender 
of exosomal miR expression




  miR-142- 3p 8.06 <0.0001 0.0001
  miR- 33a- 5p 2.73 0.0008 0.001
  let- 7d- 5p   −1.78 0.0009 0.003
Plasma exosomal miRs
  miR-142- 3p 1.64 0.008 0.039
  miR- 200c- 5p 2.21 0.012 0.028
miR, microRNA.
Figure 2 Exosomal miR-142- 3p is positively associated with sputum macrophages in IPF context. (A–C) Spearman correlation between the 
percentage of sputum macrophages and expression level of (A) exosomal miR-142- 3p, (B) exosomal miR- 33a- 5p and (C) exosomal Let- 7d- 5p from 
sputum of patients with IPF. (D–F) Spearman correlation between the percentage of sputum neutrophils and expression level of (D) exosomal miR-
142- 3p, (E) exosomal miR- 33a- 5p and (F) exosomal Let- 7d- 5p from sputum of patients with IPF. (A–F) Data are non- normally distributed and are 
analysed using Spearman correlation. IPF, idiopathic pulmonary fibrosis; miR, microRNA.
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Figure 3 miR-142- 3p represses profibrotic response to TGF-β1 by targeting TGFβ-R1 in alveolar epithelial cells and lung fibroblasts. (A) In silico 
analysis to predict functional role of IPF- related miRs (miR-142- 3p, miR- 33a- 5p and Let7d- 5p) with mirPath v.3 (Tarbase V.7 database). (B–D) MiR-
142- 3p overexpression suppresses the induction of TGFβ-R1 mRNA in (B) alveolar epithelial cell line (A549) (n=5), (C) lung fibroblast cell line (MRC5) 
(n=3) and (D) primary lung fibroblasts (HLF) (n=5), as assessed by qRT- PCR. Cells were either unstimulated or treated with TGF-β1 (5 ng/mL) for 
4 hours. Data passed the Shapiro- Wilk normality test and are expressed as mean (±SEM) and analysed using paired two- tailed t- test. (E–H) Western 
blotting analysis confirms that TGFβ-R1 protein is suppressed by the miR-142- 3p overexpression in alveolar epithelial cell line (A549) (E,F) and lung 
fibroblast cell line (MRC5) (G,H). (I–K) MiR-142- 3p overexpression reduces the induction of profibrotic genes (COL1A1 and TGF-β1) in response to 
TGF-β1 stimulation in the (I) alveolar epithelial cell line (A549) (n=5), (J) lung fibroblast cell line (MRC5) (n=3) and (K) primary lung fibroblasts (HLF) 
(n=5), as assessed by qRT- PCR. Data passed the Shapiro- Wilk normality test and are expressed as mean (±SEM) and analysed using paired two- tailed 
t- test. FDR, false discovery rate; HLF, human lung fibroblast; IPF, idiopathic pulmonary fibrosis; miR, microRNA; mRNA, messenger RNA; qRT- PCR, 
quantitative reverse transcription–PCR; TGF-β1, transforming growth factor β1; TGFβ-R1, transforming growth factor β receptor 1.
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macrophages (figure 4A). As expected, this macrophage cell line 
is enriched in miR-142- 3p compared with alveolar epithelial 
cells (A549) and lung fibroblasts (MRC5) (more than 3000- fold, 
p<0.001) (figure 4B). The isolated vesicles present an average 
size distribution of 143.4 nm (±4.4 nm) (figure 4C) and an enrich-
ment of several exosomal markers, CD81, CD9 and synthenin, 
and an absence of mitochondrial cytochrome c (figure 4D), 
which confirms the purity of our exosome preparation.
Then, we tested whether miR-142- 3p could be transferred 
to alveolar epithelial cells and lung fibroblasts via macrophage- 
derived exosomes. For this, we incubated A549 and MRC5 cells 
with THP1 macrophage exosomes for 24 hours and measured 
the expression of IPF- related miRs (figure 4E,G). The level of 
miR-142- 3p increased in A549 and MRC5 cells in the pres-
ence of macrophage- derived exosomes (2.1 fold, p=0.033, 
and 1.41 fold, p=0.034, respectively) (figure 4F,H), demon-
strating that these vesicles are able to transfer miR-142- 3p to 
target cells.
Macrophage-derived exosomes are able to suppress 
profibrotic activation in lung epithelial cells and fibroblasts
Because macrophage- derived exosomes are able to transfer 
antibrotic miR-142- 3p to target cells, we anticipated that these 
extracellular vesicles (EVs) will present antifibrotic proper-
ties in the recipient cells. To test this, we incubated A549 and 
MRC5 cells with purified THP1 macrophage- derived exosomes 
for 24 hours and treated the cells with TGF-β for 4 hours 
(figure 5A,B). Macrophage- derived exosomes were able to 
reduce TGFβ-R1 transcript in A549 epithelial cells (p=0.013) 
Figure 4 Macrophage- derived exosomes transfer miR-142- 3p to recipient alveolar epithelial cells and lung fibroblasts. (A) Schematic representation 
of the isolation of exosomes from THP1 macrophages. Macrophages were incubated for 72 hours. Then, conditioned medium was collected and 
macrophage- derived exosomes were isolated using standard ultracentrifugation protocol. (B) miR-142- 3p is highly enriched in THP1 macrophages 
compared with A549 lung epithelial cells and MRC5 fibroblasts (n=4). (C) Representative size distribution of purified THP1 macrophage- derived 
exosomes by dynamic light scattering analysis. A representative experiment of 3 is shown. The average size distribution of the vesicles is 
143.4±4.4 nm. (D) Western blot analysis of exosomal markers, CD81, CD9, synthenin and mitochondrial protein cytochrome c in THP1 macrophage- 
derived exosomes and cell lysates from THP1 cells. (E,G) Schematic representation of the treatment of A549 alveolar epithelial cells (E) and MRC5 
lung fibroblasts (G) with macrophage- derived exosomes for 24 hours. (F,H) Transcript levels of IPF- related miRs (miR-142- 5p, miR- 33a- 5p, Let- 7d- 
5p, miR-21- 5p, miR- 200c- 5p and miR- 26a- 5p) assessed by qRT- PCR in A549 alveolar epithelial cells (F) and MRC5 lung fibroblasts (H) treated with 
macrophages- derived exosomes (5 µg) for 24 hours (n=3). (B,F,H) Data passed the Shapiro- Wilk normality test and are expressed as mean (±SEM) and 
analysed using paired two- tailed t- test. IPF, idiopathic pulmonary fibrosis; miR,microRNA.
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Figure 5 Macrophage- derived exosomes present antifibrotic property. (A,B) Schematic representation of the treatment of A549 lung epithelial cells 
(A) and MRC5 fibroblasts (B) with macrophage- derived exosomes for 24 hours, followed by TGF-β1 stimulation (4 hours). (C–E) Macrophage- derived 
exosomes repress TGFβ-R1 expression at transcript (C) (n=4) and protein (D,E) levels in A549 lung epithelial cells. (F) Macrophage- derived exosomes 
repress the expression of TGFβ-R1 mRNA in MRC5 lung fibroblasts (n=4). (G,H) Macrophage- derived exosomes repress the induction of profibrotic 
genes (COL1A1, COL3A1 and TGF-β1) in response to TGF-β1 stimulation in (G) the alveolar epithelial cell line (A549) (n=4) and (H) the lung 
fibroblast cell line (MRC5) (n=4), as assessed by qRT- PCR. (C,F,G,H) Data passed the Shapiro- Wilk normality test and are expressed as mean (±SEM) 
and analysed using paired two- tailed t- test. qRT- PCR, quantitative reverse transcription PCR; TGF-β1, transforming growth factor β1; TGFβ-R1, 
transforming growth factor β receptor 1.
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and MRC5 fibroblasts (p=0.013) (figure 5C,F) and its protein 
level in A549 cells (figure 5D,E). Furthermore, they were able 
to repress the expression of profibrotic genes in the presence 
of TGF-β in A549 (COL1A1, p=0.032; COL3A1, p=0.002; 
and TGF-β1, p=0.003) and MRC5 cells (COL1A1, p=0.015; 
COL3A1, p=0.038; and TGF-β1, p=0.022) (figure 5G,H).
In order to demonstrate that miR-142- 3p is the active element 
responsible for the antifibrotic property of macrophage- derived 
exosomes, miR-142- 3p was knocked down in THP1 macro-
phages prior to exosome collection and treatment of A549 cells 
(figure 6A,B). This affects the antifibrotic property of corre-
sponding exosomes. Indeed, we observed an upregulation of the 
expression of profibrotic genes in alveolar epithelial cells treated 
with exosomes derived from miR-142- 3p inhibitor- treated 
macrophages compared with the ones derived from control 
inhibitor- treated macrophages (COL1A1, p=0.045; COL3A1, 
p=0.007; and TGF-β1, p=0.018) (figure 6D–F).
Taken together, these findings delineate a process whereby 
transfer of miR-142- 3p from macrophage- derived exosomes to 
alveolar epithelial cells and lung fibroblasts can modulate profi-
brotic gene expression and thereby could attenuate pulmonary 
fibrosis.
DISCUSSION
Exosomes have emerged as essential actors impacting the progres-
sion of fibrotic diseases by transferring antifibrotic or profibrotic 
miRs to target cells and affecting pathological fibrogenesis. The 
objective of our study was to elucidate the impact of IPF- related 
exosomal miRs on fibrogenesis. Here, we found that miR-142- 3p is 
upregulated in sputum and plasma of patients with IPF, suggesting 
that this miR influences the pathogenesis of pulmonary fibrosis. 
Correlation analysis revealed a positive association between 
exosomal miR-142- 3p and the percentage of macrophages from 
the sputum of patients with IPF, suggesting macrophage origin 
of miR-142- 3p upregulation. In accordance with our findings, 
previous studies have shown that primary macrophages, including 
sputum macrophages, express high amount of miR-142- 3p.36 37 
In addition, Squadrito et al found that macrophages are able to 
release exosomes containing miR-142- 3p, which can be transferred 
to target cells.37 An elegant study from Maes et al has shown that 
miR-142- 3p was significantly upregulated in sputum of patients 
with severe asthma.36 Interestingly, a positive correlation between 
miR-142- 3p and sputum neutrophils was observed in asthmatic 
context. Depending on pathological context, it appears that 
upregulation of sputum miR-142- 3p derives from macrophages 
or neutrophils, two sputum cell subsets expressing miR-142- 3p. 
In the study from Maes et al, the detection of miR-142- 3p was 
performed on sputum supernatants, so the miR could be either 
present in the EV fraction, which contains exosomes and microve-
sicles and/or in the EV- free fraction. It would be interesting to 
isolate exosomes from asthma sputum in order to investigate the 
expression of exosomal miR-142- 3p in the asthmatic context.
In silico analysis and functional experiments on alveolar epithe-
lial cells and lung fibroblasts transfected with mimics indicated 
that miR-142- 3p presents antifibrotic properties by modulating 
TGF-β signalling pathway via targeting the receptor TGFβ-R1. 
The major cellular sources of TGF-β production during IPF have 
been identified as alveolar macrophages, airway epithelial cells 
and lung fibroblasts.38–40 We thus favour the hypothesis that 
miR-142- 3p could slow the progression of IPF by blocking the 
production of TGF-β in airway epithelial cells and lung fibro-
blasts. In addition, we have shown that miR-142- 3p represses 
the expression of ECM- related genes (COL1A1 and COL3A1) 
which could reduce the deposition of ECM and scar formation. 
In accordance with our findings, Wang et al demonstrated that 
overexpression of miR-142- 3p represses the expression of profi-
brotic genes in cardiomyocytes by targeting high mobility group 
box 1.41 Likewise, Yang et al reported that the plasma level 
of miR-142- 3p declined significantly in patients with hepatic 
cirrhosis, and ectopic expression of miR-142- 3p in activated 
hepatic stellate cells decreased profibrotic markers.42
Chronic injury of lung tissue is an early event in IPF which leads 
to an irreversible alteration of the reparative functions of alve-
olar epithelial cells.43 One of the key factors responsible for the 
alteration of reparative capacity of alveolar epithelial cells is senes-
cence.44 The inhibition of TGF-β/TGFβ-R1 complex by exosomal 
miR-142- 3p transfer may prevent TGFβ-induced senescence in 
these cells and preserve their self- renewal capacity. In addition, 
direct repression on senescence molecular pathways via miR-142- 3p 
could also contribute alveolar repair since some key players such as 
p53 are direct targets of miR-142- 3p.45 Another study by Guo et 
al has shown that miR-142- 3p could modulate pulmonary fibrosis 
by inhibiting apoptosis and inflammation induced by bleomycin 
through down- regulation of cyclooxygenase-2.46 Recent studies 
have demonstrated the important contribution of mitochondrial 
dysfunction in initiation and maintenance of pathological fibro-
genesis.47 48 Future investigations will be needed to assess the 
impact of miR-142- 3p on alveolar epithelial cell renewal capacity 
and endoplasmic reticulum stress.
We also showed that miR-142- 3p partially represses the 
proliferation of lung fibroblast, a process playing a critical role 
in the pathogenesis of lung fibrosis. In accordance with our find-
ings, Carraro et al demonstrated that miR-142- 3p contributes 
to the proper proliferation of mesenchymal progenitors during 
lung development by controlling the level of wingless- related 
integration site (WNT) signalling.49 In addition, recent studies 
have reported the antiproliferative property of miR-142- 3p in 
tumourous context.50 51
One of the major questions in the field of EVs is the role of 
exosomes in pathological contexts, particularly lung fibrosis. 
Several studies have reported that exosomes play versatile roles, 
depending on the disease and their cell origin. Some studies have 
demonstrated that mesenchymal stem cell- derived exosomes 
are able to facilitate wound healing and blocks myofibroblastic 
differentiation in IPF context,52 53 whereas others have suggested 
deleterious effects.54 55 Those discrepancies are probably due to 
distinct cells and tissue origin of those vesicles. Here, we found 
that macrophage- derived exosomes present antifibrotic proper-
ties in vitro due in part to the transfer of miR-142- 3p to alveolar 
epithelial cells and lung fibroblasts. The upregulation of antifi-
brotic miR-142- 3p in IPF context is probably a process to fight 
against fibrogenesis. Indeed, several studies as demonstrated that 
specific miRs are upregulated in pathological context and act as 
mediators of negative feedback loop to turn down pathological 
processes.56 Our result suggest that macrophage- derived exosomes 
may fight against pulmonary fibrosis progression via the delivery of 
antifibrotic miR-142- 3p. To our knowledge, this is the first study 
mentioning the protective role of macrophage- derived exosomes 
in IPF context. A perspective of our work is the use of miR-142- 
3p- loaded exosomes as potential therapeutic tool for the treatment 
of lung fibrosis. Further investigations need to be performed on a 
mouse model of pulmonary fibrosis (eg, bleomycin model).
A limitation of our study is the use of two independent 
cohorts to study sputum- derived exosomes and plasma- derived 
exosomes. Furthermore, the size sample of both cohorts are 
small (sputum cohort (19 IPF vs 23 HS) and plasma cohort (14 
IPF vs 14 HS)) and heterogeneous. It is due to the fact that IPF 
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Figure 6 Antifibrotic property of macrophage- derived exosomes is miR-142- 3p dependent. (A) Schematic representation of the treatment of A549 
lung epithelial cells with miR-142- 3p depleted macrophage exosomes. The level of miR-142- 3p was silenced in THP1 macrophages by transfection 
of the miR-142- 3p inhibitor. After 24 hours, the culture medium was refreshed and miR-142- 3p depleted macrophage exosomes were isolated after 
additional 72 hours. Then, their impact on the modulation of the expression of profibrotic genes in A549 lung epithelial cells in the presence of TGF-β1 
was evaluated. (B) The level of miR-142- 3p was reduced in A549 cells after 24 hours of miR-142- 3p inhibitor transfection. (C–F) Inhibiting miR-142- 
3p in THP1 macrophages affects the antifibrotic property of related exosomes, as shown by their impact on the expression of TGFβ-R1 (C), COL1A1 
(D), COL3A1 (E) and TGF-β1 (F), compared to crtl inhibitor- exosomes. (B–F) Data passed the Shapiro- Wilk normality test and are expressed as mean 
(±SEM) and analysed using paired two- tailed t- test. miR, microRNA; mRNA, messenger RNA; PBS, phosphate- buffered saline; TGF-β1, transforming 
growth factor β1; TGFβ-R1, transforming growth factor β receptor 1.
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is a rare disease, which makes it difficult to generate cohorts. 
The relatively low number of studied samples of the correlation 
analysis may have contributed to borderline p values. Finally, we 
were unable to obtain IPF sputum in order to isolate sputum cell 
subsets to assess the levels of miR-142- 3p. However, in one of 
our previous studies, we have already detected the expression of 
miR-142- 3p in sputum macrophages and neutrophils.36
In summary, our study provides a new finding for the role of 
macrophage- derived exosomes in modulating fibrosis in pulmo-
nary fibrosis diseases. We propose that the antifibrotic properties 
of macrophage- derived exosomes due in part to the delivery of 
miR-142- 3p to target cells may slow the progression of pulmonary 
fibrosis by targeting excessive deposition of ECM (figure 7). The 
delivery of this antifibrotic miR in the lung could protect against 
fibrosis, revealing a new therapeutic potential to treat IPF disease.
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